According to pharmaceutical company Novartis AG, the diabetes drug Galvus is proving to be both efficient and well-tolerated by type 2 diabetics currently undergoing a clinical trial.
The study, comprising 544 patients suffering from type 2 diabetes, was given standard metformin treatment alongside diabetes drug Galvus. A contrast group were given metformin with a placebo. Four times as many patients in the galvus trial achieved recommended blood sugar control levels .
Novartis also examined a subset group, who reported an even more impressive correlation between galvus use and achieving glycaemic control. Galvus is expected to become a blockbuster drug for the medical company.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…